semaglutide vs tirzepatide weight loss effectiveness comparison for in Adults With Overweight or Obesity semaglutide vs tirzepatide dose comparison

GLP-1 agonists are licensed only for type 2 diabetes and obesity, not rheumatoid arthritis or other autoimmune conditions

Kennedy, who described himself as a big fan of peptides, has used the therapies himself

When used in addition to diet and exercise, it can cause significant weight loss and a reduced risk of cancer, diabetes, and heart disease in those who are obese and overweight

Nausea, vomiting, and diarrhoeacommon during Wegovy treatment, especially in the initial monthscan potentially affect nutrient absorption

The foods to avoid during GLP-1 treatment apply here too, particularly simple sugars and highly processed carbohydrates that cause rapid glucose spikes

GLP-1 is the backbone of obesity